Cargando…

Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy

BACKGROUND: Malignant struma ovarii is a rare malignant germ cell tumor of the ovary. Due to the rarity of this disease, treatment has not been uniform throughout the published literature. CASES: We present three cases of malignant struma ovarii. Following primary surgery, all were subsequently trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Janszen, Erica W.M., van Doorn, Helena C., Ewing, Patricia C., de Krijger, Ronald R., de Wilt, Johannes H.W., Kam, Boen L.R., de Herder, Wouter W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161682/
https://www.ncbi.nlm.nih.gov/pubmed/21892277
_version_ 1782210722149695488
author Janszen, Erica W.M.
van Doorn, Helena C.
Ewing, Patricia C.
de Krijger, Ronald R.
de Wilt, Johannes H.W.
Kam, Boen L.R.
de Herder, Wouter W.
author_facet Janszen, Erica W.M.
van Doorn, Helena C.
Ewing, Patricia C.
de Krijger, Ronald R.
de Wilt, Johannes H.W.
Kam, Boen L.R.
de Herder, Wouter W.
author_sort Janszen, Erica W.M.
collection PubMed
description BACKGROUND: Malignant struma ovarii is a rare malignant germ cell tumor of the ovary. Due to the rarity of this disease, treatment has not been uniform throughout the published literature. CASES: We present three cases of malignant struma ovarii. Following primary surgery, all were subsequently treated with thyroidectomy and (131)I ablation therapy, two patients as first line management, one following the occurrence of metastatic disease. CONCLUSION: Histological diagnosis of malignant struma ovarii is similar to that of well differentiated thyroid carcinoma (WDTC). In line with the latest advice on treatment of WDTC, we believe that the best option for patients with malignant struma ovarii is surgical removal of the ovarian lesion followed by total thyroidectomy which allows the exclusion of primary thyroid carcinoma, and in addition, allows radioiodine ((131)I) ablation therapy for (micro) metastasis. After thyroidectomy, thyroglobulin can be used as a tumor marker for follow-up. Moreover, nuclear medicine imaging using radioiodine ((123)I) can be performed to demonstrate metastatic carcinoma. A multidisciplinary approach is essential.
format Online
Article
Text
id pubmed-3161682
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-31616822011-09-02 Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy Janszen, Erica W.M. van Doorn, Helena C. Ewing, Patricia C. de Krijger, Ronald R. de Wilt, Johannes H.W. Kam, Boen L.R. de Herder, Wouter W. Clin Med Oncol Case Report BACKGROUND: Malignant struma ovarii is a rare malignant germ cell tumor of the ovary. Due to the rarity of this disease, treatment has not been uniform throughout the published literature. CASES: We present three cases of malignant struma ovarii. Following primary surgery, all were subsequently treated with thyroidectomy and (131)I ablation therapy, two patients as first line management, one following the occurrence of metastatic disease. CONCLUSION: Histological diagnosis of malignant struma ovarii is similar to that of well differentiated thyroid carcinoma (WDTC). In line with the latest advice on treatment of WDTC, we believe that the best option for patients with malignant struma ovarii is surgical removal of the ovarian lesion followed by total thyroidectomy which allows the exclusion of primary thyroid carcinoma, and in addition, allows radioiodine ((131)I) ablation therapy for (micro) metastasis. After thyroidectomy, thyroglobulin can be used as a tumor marker for follow-up. Moreover, nuclear medicine imaging using radioiodine ((123)I) can be performed to demonstrate metastatic carcinoma. A multidisciplinary approach is essential. Libertas Academica 2008-02-29 /pmc/articles/PMC3161682/ /pubmed/21892277 Text en © 2008 the author(s), publisher and licensee Libertas Academica Ltd. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license http://creativecommons.org/licenses/by/3.0/).
spellingShingle Case Report
Janszen, Erica W.M.
van Doorn, Helena C.
Ewing, Patricia C.
de Krijger, Ronald R.
de Wilt, Johannes H.W.
Kam, Boen L.R.
de Herder, Wouter W.
Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy
title Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy
title_full Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy
title_fullStr Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy
title_full_unstemmed Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy
title_short Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy
title_sort malignant struma ovarii: good response after thyroidectomy and (131)i ablation therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161682/
https://www.ncbi.nlm.nih.gov/pubmed/21892277
work_keys_str_mv AT janszenericawm malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy
AT vandoornhelenac malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy
AT ewingpatriciac malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy
AT dekrijgerronaldr malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy
AT dewiltjohanneshw malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy
AT kamboenlr malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy
AT deherderwouterw malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy